• HUMAN ISLETS FOR RESEARCH-We currently supply human islets to both the academic and corporate communities for their research related to diabetes. We pride ourselves on providing the highest quality islets, which we have been able to produce by using our proprietary media (PIM-Prodo Islet Media)

  • PRODO ISLET MEDIA (PIM)®- Our media is a cGMP product and has been designed to increase the viability and purity of the cells, from the initial recovery to the stage where the islets are ready for study and experiments. Our media is capable of long-term culturing, of up to 21 days, without loss of purity and viability. The PIM® family of products has a Biological Master File with the Food and Drug Administration (IND-15016). 

  • OUR SERVICES-Prodo Labs is capable of performing many services on a contract basis. Some of these services include performing assays, animal isolations and islet testing.

  • RESEARCH-Working in conjunction with the Scharp-Lacy Research Institute, Prodo Labs is committed to performing research which could lead to a cure for diabetes. Led by Dr. David Scharp, MD, our company continues to break new ground in battling this debilitating disease.

Welcome to Prodo Laboratories, Inc.

Prodo Laboratories is committed to providing advanced products, research and services to aid in the development of a cure for diabetes. We currently supply human islets to both the academic and corporate communities for their research related to diabetes. We pride ourselves on providing the highest quality islets, which we have been able to produce by using our proprietary media (PIM-Prodo Islet Media). Our media has been designed to increase the viablility and purity of the cells, from the initial recovery to the stage where the islets are ready for study and experiments. Please take a moment to view our product offerings and our testing services.

News

March 7, 2012
The Food and Drug Administration has granted Prodo Laboratories, Inc. a Biological Master File number for the Prodo Islet Media (PIM)®!  The BMF number is IND-15016.  Clinical testing is approved and underway at several isolation centers.
November 3, 2011
University of Pittsburgh releases poster showing that Prodo Islet Media outperforms CRML Media
(Please visit our published papers section)!
November 2, 2011
Transplantation Center testing confirms that Prodo Islet Media out performs CRML based media by a considerable margin. Worldwide testing is underway at additional centers
October 23, 2011
Prodo Laboratories is the recipient of a Phase I, NIH/SBIR Grant for Islet Encapsulation.
September 12, 2011
Prodo Labs hits the 21 million IEQ shipped mark
June 1st, 2011
Prodo Labs officially launched their cGMP Islet Culture Media (Prodo Islet Media-PIM) at the International Pancreas and Islet Transplant Association meeting in Prague. Please visit our cGMP Products section for more information.
February 14th, 2011
Prodo Labs has now shipped over 16 million islets to both the corporate and academic communities, with purity averaging 85-90% and viability averaging 95%.
November 5, 2010
Prodo Labs announces being the recipient of two new grants from the Qualifying Therapeutic Discovery Grant (QTDG) funds from a combined NIH/IRS program to provide stimulus funds to small businesses working to develop new health care products.
October 1, 2010
Prodo Labs announces its ability to begin supplying human islets from Type 2 Diabetes research pancreas donors directly to corporate and academic investigators.
July 1, 2010
Prodo Labs publishes a new article in Transplantation Proceedings regarding its success in processing large quantities of human islets from research pancreas donors with long cold ischemia times.

Mission Statement

Prodo Laboratories, Inc.'s mission is to deliver services and products to patients with diabetes and to the diabetes research community. It seeks to accomplish this goal by focusing its research and development activities on the improvement of the health and well being of all patients with diabetes.

Our Motto: "Today, Not Tomorrow"
Products

Prodo Labs provides high quality human islets for research as its primary service business by direct contracts with biotechnology and pharmaceutical companies utilizing them for in vitro and in vivo testing in the development of new drugs for diabetes or in the development of new insulin-producing cells for future transplants.

About Us

Prodo Laboratories, Inc was founded in Sept 2006 by David Scharp, MD to develop a biotechnology company that provides diabetes research services and products to both the academic and corporate diabetes research communities, as well as pursue its own research lines.